Matches in SemOpenAlex for { <https://semopenalex.org/work/W1606327354> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- W1606327354 endingPage "54" @default.
- W1606327354 startingPage "4146" @default.
- W1606327354 abstract "To provide a new tool for the immunotherapy of human ovarian carcinoma, we constructed a fusion protein between interleukin-2 (IL-2) and the single-chain Fv (scFv) of MOV19, a monoclonal antibody directed against alpha-folate receptor (alpha-FR), known to be overexpressed on human nonmucinous ovarian carcinoma. This was accomplished by fusing the coding sequences in a single open reading frame and expressing the IL-2/MOV19 scFv chimera under the control of the murine immunoglobulin K promoter in J558L plasmacytoma cells. The design allowed the construction of a small molecule combining the specificity of MOV19 with the immunostimulatory activity of IL-2. This might improve the tissue penetration and distribution of the fusion protein within the tumor, reduce its immunogenicity, and avoid the toxicity related to the systemic administration of IL-2. The IL-2/MOV19 fusion protein was stable on purification from the cell supernatant and was biologically active. Importantly, this construct was able to target IL-2 onto the surface of alpha-FR-overexpressing tumor cells and stimulated the proliferation of the IL-2-dependent CTLL-2 cell line as well as that of human resting peripheral blood lymphocytes. In a syngeneic mouse model, IL-2/MOV19 scFv specifically targeted a-FR gene-transduced metastatic tumor cells without accumulating in normal tissues, due to its fast clearance from the body. Prolonged release of IL-2/MOV19 scFv by in vivo transplanted J558-EF6.1 producer cells protected 60% of mice from the development of lung metastases caused by an i.v. injection of a-FR gene-transduced tumor cells. Moreover, treatment with IL-2/MOV19 scFv, but not with recombinant IL-2, significantly reduced the volume of s.c. tumors. The pharmacokinetics and biological characteristics of IL-2/NMOV19 scFv might allow us to combine the systemic administration of this molecule with the adoptive transfer of in vitro retargeted T lymphocytes for the treatment of ovarian cancer, thereby providing local delivery of IL-2 without toxicity." @default.
- W1606327354 created "2016-06-24" @default.
- W1606327354 creator A5037526893 @default.
- W1606327354 creator A5041835102 @default.
- W1606327354 creator A5051020039 @default.
- W1606327354 creator A5055773624 @default.
- W1606327354 creator A5056330567 @default.
- W1606327354 creator A5062210857 @default.
- W1606327354 creator A5068824599 @default.
- W1606327354 creator A5081264460 @default.
- W1606327354 creator A5087949502 @default.
- W1606327354 creator A5091716433 @default.
- W1606327354 date "1998-09-15" @default.
- W1606327354 modified "2023-09-23" @default.
- W1606327354 title "Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody." @default.
- W1606327354 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9751627" @default.
- W1606327354 hasPublicationYear "1998" @default.
- W1606327354 type Work @default.
- W1606327354 sameAs 1606327354 @default.
- W1606327354 citedByCount "23" @default.
- W1606327354 countsByYear W16063273542013 @default.
- W1606327354 countsByYear W16063273542014 @default.
- W1606327354 countsByYear W16063273542015 @default.
- W1606327354 countsByYear W16063273542016 @default.
- W1606327354 countsByYear W16063273542017 @default.
- W1606327354 countsByYear W16063273542021 @default.
- W1606327354 countsByYear W16063273542022 @default.
- W1606327354 crossrefType "journal-article" @default.
- W1606327354 hasAuthorship W1606327354A5037526893 @default.
- W1606327354 hasAuthorship W1606327354A5041835102 @default.
- W1606327354 hasAuthorship W1606327354A5051020039 @default.
- W1606327354 hasAuthorship W1606327354A5055773624 @default.
- W1606327354 hasAuthorship W1606327354A5056330567 @default.
- W1606327354 hasAuthorship W1606327354A5062210857 @default.
- W1606327354 hasAuthorship W1606327354A5068824599 @default.
- W1606327354 hasAuthorship W1606327354A5081264460 @default.
- W1606327354 hasAuthorship W1606327354A5087949502 @default.
- W1606327354 hasAuthorship W1606327354A5091716433 @default.
- W1606327354 hasConcept C104317684 @default.
- W1606327354 hasConcept C123894998 @default.
- W1606327354 hasConcept C153911025 @default.
- W1606327354 hasConcept C159654299 @default.
- W1606327354 hasConcept C203014093 @default.
- W1606327354 hasConcept C2777701055 @default.
- W1606327354 hasConcept C2780868878 @default.
- W1606327354 hasConcept C30278631 @default.
- W1606327354 hasConcept C40767141 @default.
- W1606327354 hasConcept C502942594 @default.
- W1606327354 hasConcept C542903549 @default.
- W1606327354 hasConcept C55493867 @default.
- W1606327354 hasConcept C86803240 @default.
- W1606327354 hasConcept C8891405 @default.
- W1606327354 hasConceptScore W1606327354C104317684 @default.
- W1606327354 hasConceptScore W1606327354C123894998 @default.
- W1606327354 hasConceptScore W1606327354C153911025 @default.
- W1606327354 hasConceptScore W1606327354C159654299 @default.
- W1606327354 hasConceptScore W1606327354C203014093 @default.
- W1606327354 hasConceptScore W1606327354C2777701055 @default.
- W1606327354 hasConceptScore W1606327354C2780868878 @default.
- W1606327354 hasConceptScore W1606327354C30278631 @default.
- W1606327354 hasConceptScore W1606327354C40767141 @default.
- W1606327354 hasConceptScore W1606327354C502942594 @default.
- W1606327354 hasConceptScore W1606327354C542903549 @default.
- W1606327354 hasConceptScore W1606327354C55493867 @default.
- W1606327354 hasConceptScore W1606327354C86803240 @default.
- W1606327354 hasConceptScore W1606327354C8891405 @default.
- W1606327354 hasIssue "18" @default.
- W1606327354 hasLocation W16063273541 @default.
- W1606327354 hasOpenAccess W1606327354 @default.
- W1606327354 hasPrimaryLocation W16063273541 @default.
- W1606327354 hasRelatedWork W1977431614 @default.
- W1606327354 hasRelatedWork W2353794996 @default.
- W1606327354 hasRelatedWork W2364443116 @default.
- W1606327354 hasRelatedWork W2367342778 @default.
- W1606327354 hasRelatedWork W2375137512 @default.
- W1606327354 hasRelatedWork W2377766327 @default.
- W1606327354 hasRelatedWork W2378866360 @default.
- W1606327354 hasRelatedWork W2379207653 @default.
- W1606327354 hasRelatedWork W2394525459 @default.
- W1606327354 hasRelatedWork W2410251327 @default.
- W1606327354 hasVolume "58" @default.
- W1606327354 isParatext "false" @default.
- W1606327354 isRetracted "false" @default.
- W1606327354 magId "1606327354" @default.
- W1606327354 workType "article" @default.